Name: CUREVAC NV (5CV) Stock
Brand: CUREVAC NV
Rating: 4 (3 reviews)

Question 1

Can you describe the business of CUREVAC NV?

Accepted Answer

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

Question 2

Can you provide the latest stock price for CUREVAC NV?

Accepted Answer

The current stock price of 5CV.DE is 3.536 EUR. The price increased by 4.12% in the last trading session.

Question 3

Does 5CV stock pay dividends?

Accepted Answer

5CV.DE does not pay a dividend.

Question 4

How is the ChartMill rating for CUREVAC NV?

Accepted Answer

5CV.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.

Question 5

What is the GICS sector and industry of 5CV stock?

Accepted Answer

CUREVAC NV (5CV.DE) operates in the Health Care sector and the Biotechnology industry.

Question 6

What is CUREVAC NV worth?

Accepted Answer

CUREVAC NV (5CV.DE) has a market capitalization of 796.20M EUR. This makes 5CV.DE a Small Cap stock.

Question 7

Can you provide the upcoming earnings date for CUREVAC NV?

Accepted Answer

CUREVAC NV (5CV.DE) will report earnings on 2026-04-08, after the market close.

CUREVAC NV (5CV.DE) Stock Price, Forecast & Analysis

5CV.DE Latest News, Press Relases and Analysis